Supernus Pharmaceuticals is a biopharmaceutical company focused on central nervous system diseases that develops and commercializes a diverse portfolio of branded medications across indications including ADHD, Parkinson's disease, postpartum depression, epilepsy, migraine, and movement disorders. The company sells its products primarily through pharmaceutical wholesalers and specialty pharmacies to psychiatrists, movement disorder specialists, pediatricians, and other healthcare providers treating CNS conditions. Revenue derives from direct product sales, milestone payments, and royalties from out-licensing arrangements, with the company employing proprietary formulation technologies and maintaining patent-protected products supported by dedicated U.S. sales forces.